The role of insulin‐like growth factors signaling in merlin‐deficient human schwannomas
Abstract
Loss of the tumor suppressor merlin causes development of the tumors of the nervous system, such as schwannomas, meningiomas, and ependymomas occurring spontaneously or as part of a hereditary disease Neurofibromatosis Type 2 (NF2). Current therapies, (radio) surgery, are not always effective. Therefore, there is a need for drug treatments for these tumors. Schwannomas are the most frequent of merlin-deficient tumors and are hallmark for NF2. Using our in vitro human schwannoma model, we demonstrated that merlin-deficiency leads to increased proliferation, cell–matrix adhesion, and survival. Increased proliferation due to strong activation of extracellular-signal-regulated kinase 1/2 (ERK1/2) is caused by overexpression/activation of platelet-derived growth factor receptor-β (PDGFR-β) and ErbB2/3 which we successfully blocked with AZD6244, sorafenib, or lapatinib. Schwannoma basal proliferation is, however, only partly dependent on PDGFR-β and is completely independent of ErbB2/3. Moreover, the mechanisms underlying pathological cell–matrix adhesion and survival of schwannoma cells are still not fully understood. Here, we demonstrate that insulin-like growth factor-I receptor (IGF-IR) is strongly overexpressed and activated in human primary schwannoma cells. IGF-I and -II are overexpressed and released from schwannoma cells. We show that ERK1/2 is relevant for IGF-I-mediated increase in proliferation and cell–matrix adhesion, c-Jun N-terminal kinases for increased proliferation and AKT for survival. We demonstrate new mechanisms involved in increased basal proliferation, cell–matrix adhesion, and survival of schwannoma cells. We identified therapeutic targets IGF-IR and downstream PI3K for treatment of schwannoma and other merlin-deficient tumors and show usefulness of small molecule inhibitors in our model. PI3K is relevant for both IGF-IR and previously described PDGFR-β signaling in schwannoma.Keywords
This publication has 59 references indexed in Scilit:
- Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2Neuro-Oncology, 2011
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and ActivityCancer Cell, 2011
- ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannomaNeuro-Oncology, 2010
- SUMOylation Mediates the Nuclear Translocation and Signaling of the IGF-1 ReceptorScience Signaling, 2010
- Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the NucleusCell, 2010
- PAK kinase regulates Rac GTPase and is a potential target in human schwannomasExperimental Neurology, 2009
- Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cellsEuropean Journal of Cancer, 2009
- Merlin and the ERM proteins – regulators of receptor distribution and signaling at the cell cortexTrends in Cell Biology, 2009
- Methylprednisolone inhibits interleukin-17 and interferon-gamma expression by both naive and primed T cellsBMC Immunology, 2008
- Dissecting and Targeting the Growth Factor–Dependent and Growth Factor–Independent Extracellular Signal-Regulated Kinase Pathway in Human SchwannomaCancer Research, 2008